Should Yahoo be sold?
Rekordernes år bare ikke for kursen

Rekordernes år bare ikke for kursen

Markedet har aldrig ret. Sådan kan Conference Call fra igår opsummeres for et af vores portefølje selskaber. Selskabet kom med regnskab d. 15 oktober og er - for at sige det mildt - forvirrede - over at selskabets rekord år, som gælder både for indtjening, inflow af penge og udbytte alligevel har betydet at kursen ligger på samme niveau som ved årets start. …

Read more.

The gateway to small- and midcap stocks in Scandinavia. Steen has more than 15 years hands-on expericence in analysing and investing in stocks. He is a weekly contributor and analyst in “Aktieugebrevet”, one of the leading sources of independent analysis in Denmark.

Peter Hildebrandt, also known as “Akademikeren”, has been investing for more than 17 years. Mainly invests in Undervalued technology and biotech stocks and is currently rotating towards dividend stocks in energy and shipping.

I’m a ten year veteran of biotechnology, and currently pursuing my MBA from UCLA.  I use my knowledge of the industry and business to make my investing decisions.  I look for small to mid-cap biotech companies with innovative research and buy into their company during clinical trials.

Andreas is providing stock tips with deep fundamental research behind each stock he recommends. He is privately a portfolio manager at his own Investment company where he Invest in stocks, options, CFD’s etc. with a balanced long/short approach.

Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities.